/
1.Exploration revealed no pleural effusion or adhesions. The lung fissures were well developed. A lesion was located in the apicoposterior segment of the left upper lobe, with pleural retraction at the site of the lesion. 2.The tumor measured approximat
Left Upper Lobe Resection Specimen: 1.(Left) Lung (upper lobe): Peripheral malignant tumor. The histological and immunophenotypic features are consistent with adenosquamous carcinoma. The tumor invades the pleura. 2.Bronchial stump: No carcinoma identif
1.Left upper lobe resection specimen measuring 20 × 11 × 2.5 cm. 2.A peripheral tumor was identified 1.5 cm from the bronchial stump, which had been previously sectioned intraoperatively, measuring 3.0 × 3.0 × 2.5 cm. 3.The cut surface appeared gray-whi
Age：67
Gender：
Surgical Date：2021.07.19
Personal History：Diagnosed with tuberculosis 6 months ago; currently on regular anti-tuberculosis therapy. History of lacunar cerebral infarction for 10 years. No history of exposure to dust, toxins, or radioactive substances.
Family history：Father deceased (cause unknown); mother and children are healthy.
Smoking and drinking history：
Tumor size：3.0cmx3.0cmx2.5cm
Histological diagnosis：Mediastinoscopy was not performed. On July 9, 2021, a bronchoscopy was conducted, and pathology from the left upper lobe biopsy revealed non–small cell lung carcinoma (NSCLC), favoring poorly differentiated squamous cell carcinoma.
Immunohistochemistry：CK5/6 (+), p40 (+), CK7 (+), CK18 (+), Ki-67 (+, focal ~60%), MLH1 (+), PMS2 (+), MSH6 (+), MSH2 (+), EMA (+), SP-B (+, few cells), TTF-1 (+, partial cells), Vimentin (−), Syn (−), CD34 (−), D2-40 (−).
Grade：II
TNM：T2aN0M0
Stage：IB
Gleason Score：/
Gleason Grade：/
Tumor content (%)：0.7
Necrosis content (%)：0
Treatment Regimen：Systemic chemotherapy
Disease Progression：Chemotherapy Regimen: Paclitaxel (albumin-bound): 300 mg IV on Day 1 Cisplatin: 100 mg IV on Day 1 First cycle: October 7, 2021 Planned total: 6 cycles
Follow Up：Alive
